Oral Steroids for Immediate Treatment of Alopecia Areata
Oral corticosteroids have limited evidence for treating sudden patchy alopecia areata and should generally be avoided as first-line therapy, with intralesional corticosteroids being the preferred approach for limited patchy disease. 1
Evidence Quality and Treatment Hierarchy
The British Association of Dermatologists guidelines explicitly state that while oral prednisolone (40 mg daily, tapered over 6 weeks) showed 30-47% of patients achieving >25% hair regrowth in one small partly controlled study, this represents weak evidence (Strength of recommendation C, Quality of evidence III). 1
The fundamental problem with oral steroids is that they do not alter the disease course—only temporarily suppress it. 1 Multiple studies confirm that hair loss recurs in virtually all patients upon discontinuation or tapering of systemic corticosteroids. 2
When Oral Steroids Might Be Considered
Pulsed Oral Corticosteroid Protocols
If you choose to use oral steroids despite the limitations, pulsed regimens show better risk-benefit profiles than continuous therapy:
- 300 mg oral prednisolone monthly pulses: Showed 58-64% complete or cosmetically acceptable response in patients with >40% scalp involvement 3, 4
- Response typically evident after 2-4 months 4
- Better tolerated than continuous high-dose therapy
- Still carries 15-18% adverse event rate 3
Predictors of Poor Response
Do not use oral steroids if the patient has:
- Nail involvement (P=0.001) 3
- Associated autoimmune disease (P=0.017) 3
- Alopecia universalis (P=0.050) 3
- Disease duration >2 years 5
Preferred Alternative: Intralesional Corticosteroids
For limited patchy alopecia areata, intralesional triamcinolone acetonide (5-10 mg/mL) is the evidence-based first-line treatment (Strength of recommendation B, Quality of evidence III). 1, 6
- 62% achieved complete regrowth with monthly injections 1
- Best results: fewer than 5 patches, each <3 cm diameter 1
- Effect lasts approximately 9 months 1
- Inject 0.05-0.1 mL just beneath the dermis, producing 0.5 cm diameter hair tufts 1
Critical Management Principle
Up to 80% of patients with limited patchy hair loss of <1 year duration experience spontaneous remission. 1 The guidelines emphasize that "leaving alopecia areata untreated is a legitimate option for many patients" given that the disease has no direct impact on general health. 1
Reassurance alone is appropriate, with the caveat that regrowth cannot be expected within 3 months of any individual patch developing. 1
Common Pitfalls to Avoid
Do not use continuous oral steroids long-term—the inevitable relapse upon discontinuation combined with systemic side effects makes this approach untenable 1, 2
Do not expect oral steroids to prevent disease spread or relapse—they only temporarily suppress active inflammation 2
Topical corticosteroids are widely used but lack convincing efficacy—a randomized controlled trial of desoximetasone cream failed to show significant benefit over placebo 1, 6
Weight gain occurs in all patients on systemic steroids, with additional risks of steroid acne (23% of cases) 7
Practical Algorithm
For sudden patchy alopecia areata:
Limited patches (<5 patches, <3 cm each): Intralesional triamcinolone acetonide monthly 1, 6
Extensive patchy disease (>40% scalp): Consider contact immunotherapy (DPCP/SADBE) if available—this is the only treatment with reasonable evidence for extensive disease 1, 6
If oral steroids are absolutely necessary: Use pulsed prednisolone 300 mg monthly for 4-6 months, but only if disease duration <2 years and no nail involvement 3, 4
Alopecia totalis/universalis: Oral steroids have particularly poor outcomes in these severe forms 2—contact immunotherapy remains the best option despite only 17% response rates 1
The evidence consistently shows that no treatment alters the underlying disease course, making the risk-benefit calculation for systemic steroids unfavorable in most clinical scenarios. 1